Ollin Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason Ehrlich, M.D., Ph.D., co-founder and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 4:00 p.m. PT. Dr. Ehrlich will provide an overview of the company’s pipeline, including OLN324, a higher potency, higher molar